Literature DB >> 25542450

Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

Momar Diouf1, Franck Bonnetain2, Jean-Claude Barbare2, Olivier Bouché2, Laetitia Dahan2, Xavier Paoletti2, Thomas Filleron2.   

Abstract

BACKGROUND: Health-related quality of life (QoL) has been validated as a prognostic factor for cancer patients; however, to be used in routine practice, QoL scores must be dichotomized. Cutoff points are usually based on arbitrary percentile values. We aimed to identify optimal cutoff points for six QoL scales and to quantify their added utility in the performance of four prognostic classifications in patients with hepatocellular carcinoma (HCC).
METHODS: We reanalyzed data of 271 patients with advanced HCC recruited between July 2002 and October 2003 from 79 institutions in France in the CHOC trial, designed to assess the efficacy of long-acting octreotide. QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30). The scores ranged from 0 to 100. Identification of optimal cutoff points was based on the method of Faraggi and Simon [Stat Med 1996;15:2203-2213]. Improvement in the performance of prognostic classifications was studied with Harrell's C-index, the net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
RESULTS: We found that optimal cutoff points were 50 for global health, 58.33 for physical functioning, 66.67 for role functioning, 66.67 for fatigue, 0 for dyspnea, and 33.33 for diarrhea. The addition of QoL and clinical factors improved the performance of all four prognostic classifications, with improvement in the range of 0.02-0.09 for the C-index, 0.24-0.78 for 3-month NRI, and 0.02-0.10 for IDI.
CONCLUSION: These cutoff values for QoL scales can be useful to identify HCC patients with very poor prognosis and thus improve design of clinical trials and treatment adjustment for these patients. ©AlphaMed Press.

Entities:  

Keywords:  Hepatocellular carcinoma; Optimal cutoff point; Prognostic classification; Quality of life

Mesh:

Year:  2014        PMID: 25542450      PMCID: PMC4294602          DOI: 10.1634/theoncologist.2014-0175

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  27 in total

1.  Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection.

Authors:  Kristel Van Steen; Desmond Curran; Jocelyn Kramer; Geert Molenberghs; Ann Van Vreckem; Andrew Bottomley; Richard Sylvester
Journal:  Stat Med       Date:  2002-12-30       Impact factor: 2.373

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

3.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

4.  Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.

Authors:  Caroline Tournoux-Facon; Xavier Paoletti; Jean-Claude Barbare; Olivier Bouché; Philippe Rougier; Laetitia Dahan; Catherine Lombard-Bohas; Roger Faroux; Jean Luc Raoul; Laurent Bedenne; Franck Bonnetain
Journal:  J Hepatol       Date:  2010-08-20       Impact factor: 25.083

5.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

6.  Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma.

Authors:  W Yeo; F K F Mo; J Koh; A T C Chan; T Leung; P Hui; L Chan; A Tang; J J Lee; T S K Mok; P B S Lai; P J Johnson; B Zee
Journal:  Ann Oncol       Date:  2006-04-06       Impact factor: 32.976

7.  Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials.

Authors:  Franck Bonnetain; Xavier Paoletti; Sandra Collette; Michel Doffoel; Olivia Bouché; Jean Luc Raoul; Philippe Rougier; Fadil Masskouri; Jean Claude Barbare; Laurent Bedenne
Journal:  Qual Life Res       Date:  2008-07-10       Impact factor: 4.147

Review 8.  The prognostic significance of patient-reported outcomes in cancer clinical trials.

Authors:  Carolyn C Gotay; Crissy T Kawamoto; Andrew Bottomley; Fabio Efficace
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

9.  The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.

Authors:  Momar Diouf; Thomas Filleron; Jean-Claude Barbare; Loïc Fin; Carl Picard; Olivier Bouché; Laetitia Dahan; Xavier Paoletti; Franck Bonnetain
Journal:  J Hepatol       Date:  2012-11-22       Impact factor: 25.083

10.  Dichotomizing continuous predictors in multiple regression: a bad idea.

Authors:  Patrick Royston; Douglas G Altman; Willi Sauerbrei
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

View more
  8 in total

1.  Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Authors:  Benjamin Houdu; Charline Lasnon; Idlir Licaj; Guy Thomas; Pascal Do; Anne-Valerie Guizard; Cédric Desmonts; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-14       Impact factor: 9.236

2.  Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Authors:  Felicia T Roncolato; Florence Joly; Rachel O'Connell; Anne Lanceley; Felix Hilpert; Luke Buizen; Aikou Okamoto; Eriko Aotani; Sandro Pignata; Paul Donnellan; Amit Oza; Elisabeth Avall-Lundqvist; Jonathan S Berek; Florian Heitz; Amanda Feeney; Dominique Berton-Rigaud; Martin R Stockler; Madeleine King; Michael Friedlander
Journal:  Oncologist       Date:  2017-06-08

3.  Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.

Authors:  Momar Diouf; Thomas Filleron; Anne-Laure Pointet; Anne-Claire Dupont-Gossard; David Malka; Pascal Artru; Mélanie Gauthier; Thierry Lecomte; Thomas Aparicio; Anne Thirot-Bidault; Céline Lobry; Francine Fein; Olivier Dubreuil; Bruno Landi; Aziz Zaanan; Julien Taieb; Franck Bonnetain
Journal:  Qual Life Res       Date:  2015-11-28       Impact factor: 4.147

4.  Trait Emotional Intelligence and School Burnout Discriminate Between High and Low Alexithymic Profiles: A Study With Female Adolescents.

Authors:  Eleonora Farina; Alessandro Pepe; Veronica Ornaghi; Valeria Cavioni
Journal:  Front Psychol       Date:  2021-07-08

Review 5.  Value of quality of life analysis in liver cancer: A clinician's perspective.

Authors:  Leung Li; Winnie Yeo
Journal:  World J Hepatol       Date:  2017-07-18

6.  Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.

Authors:  Leung Li; Frankie Kf Mo; Stephen L Chan; Edwin P Hui; Nelson Sl Tang; Jane Koh; Linda Ks Leung; Annette Ny Poon; Joyce Hui; Cheuk M Chu; Kit F Lee; Brigette By Ma; Paul Bs Lai; Anthony Tc Chan; Simon Ch Yu; Winnie Yeo
Journal:  BMC Cancer       Date:  2017-01-04       Impact factor: 4.430

Review 7.  Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018.

Authors:  Danbee Kang; Sungkeun Shim; Juhee Cho; Hyo Keun Lim
Journal:  Korean J Radiol       Date:  2020-06       Impact factor: 3.500

8.  Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors-results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS).

Authors:  Salome Adam; Melissa S Y Thong; Eva Martin-Diener; Bertrand Camey; Céline Egger Hayoz; Isabelle Konzelmann; Seyed Mohsen Mousavi; Christian Herrmann; Sabine Rohrmann; Miriam Wanner; Katharina Staehelin; Räto T Strebel; Marco Randazzo; Hubert John; Hans-Peter Schmid; Anita Feller; Volker Arndt
Journal:  Support Care Cancer       Date:  2021-04-13       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.